1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 47 results for "Indolent B-Cell Lymphoma (IBCL)".

$Thumbnail for Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma$

IBCL - 141

Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma

Javier Munoz

Poster Presenter: Javier Munoz

IBCL - 1414

Racial Disparities in Patients Hospitalized With Follicular Lymphoma. A National Inpatient Retrospective Analysis.

Oscar Borja-Montes

Poster Presenter: Oscar Borja-Montes

SOHO 2026 Annual Meeting

Topics

Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma

Racial Disparities in Patients Hospitalized With Follicular Lymphoma. A National Inpatient Retrospective Analysis.

Real-World Inpatient Outcomes Associated With Caplacizumab Use in Immune Thrombotic Thrombocytopenic Purpura: A National Inpatient Sample Analysis

Validation of Baseline Total Metabolic Tumor Volume (TMTV) and Total Lesion Glycolysis (TLG) as Predictors of Early Progression (POD24) in Follicular Lymphoma: A Retrospective Study of 100 Patients in Brazil

Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment (Tx) Effect of Epcoritamab (E) With Lenalidomide and Rituximab (R2) in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Efficacy of BRAF Inhibitors Plus Rituximab in Relapsed or Refractory Hairy Cell Leukemia: A Systematic Review and Meta-Analysis

Sociodemographic Factors and Treatment Patterns Associated With Overall Survival in Splenic Marginal Zone Lymphoma: A Nationwide Retrospective Cohort Study (2000-2022)

Concomitant Proton Pump Inhibitors Do Not Worsen Immune Checkpoint Inhibitor Outcomes Despite a Prognostically Unfavorable Baseline BMI Imbalance: A Real-World Confounder Analysis

Clinicodemographic Predictors of Outcome in Lymphoplasmacytic Lymphoma: Insights From a SEERStat Multivariate Model